<DOC>
	<DOCNO>NCT00242827</DOCNO>
	<brief_summary>An Open-Label Study Efficacy Safety Oral CEP-701 Treatment Patients Advanced Multiple Myeloma .</brief_summary>
	<brief_title>Efficacy Safety Oral CEP-701 Treatment Patients With Advanced Multiple Myeloma</brief_title>
	<detailed_description>An Open-Label Study Efficacy Safety Oral CEP-701 Treatment Patients Advanced Multiple Myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Patients include study follow criterion meet : Histological cytological confirmation stage II III multiple myeloma . Relapsed primary refractory multiple myeloma , 1 course standard therapy , progressive disease . ECOG performance status 01 . Measurable disease define serum M protein 1.0 gm/dl , serum light chain 200 mg/dL , BenceJones proteinuria 200mg/24 hour . At least 18 year age . Normal marrow function : ANC &gt; 1.0x10 9/L , platelet &gt; 50X10 9/L An exception allow myelosuppression thrombocytopenia secondary bone marrow plasmacytosis . Growth factor support allow . Normal organ function : bilirubin &lt; 1.5XULN , AST ALT &lt; 2XULN , serum creatinine &lt; 2.0 mg/dL . Contraceptive measure participation appropriate . Willing able comply study procedure restriction . Signed write informed consent . Patients exclude participate study 1 follow criterion meet : Nonsecretory disease plasma cell leukemia ( define &gt; 2000 circulate plasma cells/uL ) . More 4 prior course anticancer therapy ( bisphosphonates consider anticancer therapy criterion ) Chemotherapy radiotherapy within 4 week prior enrollment Unresolved adverse event uncontrolled illness would likely interfere objective study . Treatment investigational drug within 4 week first day study treatment History second cancer ( except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient disease free 5 year ) . Treatment potent CYP3A4 inhibitor include cyclosporine , clotrimazole , fluconazole , itraconazole , ketoconazole , voriconazole , erythromycin , clarithromycin , troleandomycin , human immunodeficiency virus ( HIV ) , protease inhibitor , nefazodone within 1 week ( 7 day ) plan 1st day study treatment . Currently receive warfarin . Clinical diagnosis active gastrointestinal ulceration melena hematemesis previous 4 week . Hypersensitivity CEP701 component CEP701 . Intolerance dexamethasone . Requirement HIV protease inhibitor treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>